Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
16h
Investor Outlook: Eli Lilly delivers another strong quarter as demand for GLP-1 drugs accelerates
Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...
Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...
The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.
On October 27, 2025, Eli Lilly announced that the U.S. FDA approved a new, once-monthly single-injection maintenance regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback